Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Strategies for Transfusion of Platelets (SToP)

This study has been terminated.
(Stopped at the request of the Data Safety Monitoring Board for safety reasons.)
Dartmouth-Hitchcock Medical Center
Haukeland University Hospital
Ottawa Hospital Research Institute
Cedars-Sinai Medical Center
University Health Network, Toronto
Information provided by:
McMaster University Identifier:
First received: January 8, 2007
Last updated: May 27, 2008
Last verified: May 2008
To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.

Condition Intervention Phase
Procedure: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Health Services Research
Official Title: Strategies for Transfusion of Platelets (SToP) [Formerly Titled "Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy"]

Resource links provided by NLM:

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Daily hemostatic assessments will be conducted to determine presence of WHO Grade 2 bleeding or greater.

Secondary Outcome Measures:
  • Number of platelets transfused during a defined period of thrombocytopenia
  • Number of platelet transfusion events(frequency)
  • Number of platelets transfused and frequency per thrombocytopenic day
  • Mean duration of thrombocytopenia
  • Percentage of days at risk of bleeding
  • Differences in the severity of bleeding between treatment groups
  • Correlation between the actual platelet dose given per transfusion for each patient and bleeding on the day following transfusion
  • Correlation between the actual number between the actual number of platelets transfused/kg body weight for each patient and bleeding on the day following transfusion
  • Pre- and post-transfusion bleeding grade in response to the dose of therapeutic platelets transfused
  • Surrogate outcomes for hemostatic efficacy including death due to bleeding as the primary and contributory cause of mortality
  • Platelet transfusion given above trigger
  • Platelet transfusion more often than once a day
  • Platelet transfusion given above their assigned dose in each case because of >/= WHO Grade 2 bleeding
  • Number of platelets transfused
  • Frequency of transfusions and duration of transfusions given because of bleeding
  • Total number of RBC transfusions
  • The mean per thrombocytopenic day for each patient
  • Platelet response (pre-transfusion platelet counts, post-transfusion platelet counts, platelet increments, and corrected platelet count increments (at 1 and/or 24 hours)
  • Cost analysis.

Enrollment: 130
Study Start Date: October 2003
  Show Detailed Description


Ages Eligible for Study:   17 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hypoproliferative thrombocytopenia who are expected to have a platelet count of ≤ 10,000/µL (10x10^9/L) for ≥ 10 days (Note: the prophylactic platelet trigger may be higher than10,000/µL (10x10^9/L) in some participating institutions; however, the patient will still be eligible for participation as long as they are expected to be thrombocytopenic for 10 days)
  • Must be an inpatient.
  • Weight between 40 and 100 kg.

Exclusion Criteria:

  • Diagnosis of promyelocytic leukemia.
  • A history or current diagnosis of immune thrombocytopenia (ITP), thrombotic thrombocytopenia (TTP), or hemolytic uremia syndrome (HUS).
  • Evidence of ≥ WHO Grade 2 bleeding while being assessed for the study entry.
  • Patients who will receive bedside Leukoreduced platelet transfusions.
  • Patients who are pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00420914

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Canada, Ontario
McMaster University
Hamilton, Ontario, Canada, L8N3Z5
Ottawa Health Research Institute
Ottawa, Ontario, Canada, K1H 8L6
University Health Network
Toronto, Ontario, Canada, M5G2M9
Haukeland University Hospital
Bergen, Norway
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Dartmouth-Hitchcock Medical Center
Haukeland University Hospital
Ottawa Hospital Research Institute
Cedars-Sinai Medical Center
University Health Network, Toronto
Principal Investigator: Nancy M Heddle, MSc., FCSMLS(D) McMaster University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00420914     History of Changes
Other Study ID Numbers: SToP Study
Study First Received: January 8, 2007
Last Updated: May 27, 2008

Keywords provided by McMaster University:

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases processed this record on May 25, 2017